But almost overnight, these cutting-edge RNA vaccine efforts have leaped forward as top candidates to fight covid-19. Some developers plan to have tens of millions of doses ready by the end of the year.Elegant in theory, efficacious in the laboratory but untested in the real world, the possible RNA vaccines are especially attractive because they…
CLOSE A Los Angeles County test is looking for pivotal information about whether people can develop immunity that helps them fight off future infections. USA TODAYCompanies are lining up to market an emerging type of blood test to detect whether a person has ever had the novel coronavirus. These antibody tests could be critical to…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f